Paratek Pharmaceuticals Stock News

BOSTON, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies fo

Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk , on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 mill

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Parate

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization o

BOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of no

BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of no

NEW YORK , Aug. 22, 2023 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc. ("Paratek" or the "C

STAMFORD, Conn.--(BUSINESS WIRE)--Abbott Cooper PLLC announces that it is investigating Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) (“Paratek” or the “Company”) on behalf of the Company's inv

Paratek Pharmaceuticals (PRTK) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.33 per share a year ago.

-- NUZYRA® (omadacycline) Net U.S. Sales of $33.8 Million from the Core Commercial Business, a 35% Increase Over Second Quarter 2022

Transaction Provides Paratek Stockholders with Immediate Value and Liquidity Stockholders to Receive Upfront Cash Payment of $2.15 per Share and a Contingent Value Right of $0.85 per Share on Achievem

NEW YORK , July 12, 2023 /PRNewswire/ --  The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Paratek Pharmaceuticals, Inc. (" Paratek" or the

Plans to Investigate All Records to Ensure Board Did Not Breach Fiduciary Duty DALLAS , July 11, 2023 /PRNewswire/ -- NexPoint Event Driven Fund today issued a demand letter to the Board of Directors

-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024

Although the equities sector recovered reasonably well from 2022's harsh glare, rising headwinds force consideration of cheap growth stocks to buy now. Essentially, some enterprises with upside potent